---
layout: post
title: "Expansion of Induction of Buprenorphine via Telemedicine Encounter"
date: 2026-02-05 18:35:45 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-04217
original_published: 2023-03-01 00:00:00 +0000
significance: 8.00
---

# Expansion of Induction of Buprenorphine via Telemedicine Encounter

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** March 01, 2023 00:00 UTC
**Document Number:** 2023-04217

## Summary

The Drug Enforcement Administration (DEA) is amending its regulations, in concert with the Department of Health and Human Services (HHS), to expand the circumstances under which individual practitioners are authorized to prescribe schedule III-V narcotic drugs or combinations of such drugs that have been approved for use in continuous medical treatment (also referred to as maintenance) or withdrawal management treatment (also referred to as detoxification)-- via a telemedicine encounter, including an audio-only telemedicine encounter.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/03/01/2023-04217/expansion-of-induction-of-buprenorphine-via-telemedicine-encounter)
- API: https://www.federalregister.gov/api/v1/documents/2023-04217

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
